Georgiamune

Georgiamune Inc. is a clinical stage biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system against diseases. Its lead program, GIM-122, is a first-in-class dual-functioning monoclonal antibody designed to overcome immunotherapy resistance in cancer patients. In August 2023, Georgiamune secured clearance from the US Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for GIM-122. The company plans to initiate a phase 1/2 clinical trial in the second half of 2023 to evaluate GIM-122's safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity as a single agent in adults with advanced solid malignancies who failed checkpoint inhibitor treatment. In addition to its lead candidate, Georgiamune is developing a pipeline of first-in-class therapies for cancer and autoimmune diseases with high unmet needs.

Key customers and partnerships

In October 2023, Georgiamune partnered with Verily, an Alphabet precision health technology company, to advance novel cancer therapeutics. The collaboration will deploy Verily's advanced molecular and real-world evidence solutions to support biomarker discovery and efficient clinical development of Georgiamune's candidates, including GIM-122. Verily's Immune Profiler will be used to assess GIM-122's pharmacodynamic effects and patients' immune responses in the ongoing phase 1/2 trial. The partnership aims to identify patient populations most likely to benefit from Georgiamune's therapies and provide holistic analysis of participant responses over time.